Details

Autor(en) / Beteiligte

• Kubicka, S.
• André, T.
• von Moos, R.
• Österlund, P.
• Reyes-Rivera, I.
• Müller, T.
• Arnold, D.
• Balcke, P.
• Benedicic, B.
• Eisterer, W.
• Fridrik, M.
• Samonigg, H.
• Arts, J.
• De Man, M.
• Janssens, J.
• Benczikova, B.
• Prausova, J.
• Vitek, P.
• Jensen, B.B.
• Keldsen, N.
• Østerlind, K.
• Borg, C.
• Breysacher, G.
• Chone, L.
• Dourthe, L.-M.
• Faroux, R.
• Illory, J.F.
• Lecomte, T.
• Legoux, J.-L.
• Levache, B.
• Lotz, J.-P.
• Mabro, M.
• Manfredi, S.
• Matysiak Budnik, T.
• Miglianico, L.
• Pezet, D.
• Porneuf, M.
• Tournigand, C.
• Viret, F.
• Ychou, M.
• Bangerter, M.
• Bertram, M.E.
• Bohnsteen, B.
• Cordes, H.-J.
• Eggert, J.
• Engel, E.
• Florschütz, A.
• Freier, W.
• Freund, M.
• Göhler, T.
• Hagen, V.
• Hebart, H.F.
• Heike, M.
• Höffkes, H.-G.
• Kettner, E.
• Kneba, M.
• Kojouharoff, G.
• Kretzschmar, A.
• Kröning, H.
• Lammert, F.
• Papke, J.
• Rädle, J.
• Ridwelski, K.
• Rudi, J.
• Schmalenberger, A.
• Schwarzer, A.
• Schwerdtfeger, M.
• Selbach, J.
• Staib, P.
• Stauch, M.
• Steffens, C.-C.
• Stübs, P.
• Tischendorf, J.
• Tummes, D.
• Von Wichert, G.P.L.
• Zomorodbaksch, B.
• Bloemendal, H.J.
• Guren, T.
• Soerbye, H.
• Fragoso, R.
• Mellidez, J.C.
• Darwish, T.
• Aparicio, J.
• Aranda, E.
• Camara, J.C.
• Donnay, O.
• Escudero, P.
• Gallego Plazas, J.
• Gonzalez Flores, E.
• Gravalos, C.
• Guardeno, R.
• Juárez, A.
• Massuti Sureda, B.
• Tobena, M.
• Toral, J.C.
• Valenti, V.
• Berglund, A.
• Fernebro, E.
• Hess-Umbricht, V.
• Popescu, R.

Titel

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Ist Teil von

• Annals of oncology, 2013-09, Vol.24 (9), p.2342-2349

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy. Evaluating outcomes according to tumor Kirsten rat sarcoma virus oncogene (KRAS) status was an exploratory analysis. KRAS data were collected from local laboratories (using their established methods) and/or from a central laboratory (mutation-specific Scorpion amplification-refractory mutation system). No adjustment was made for multiplicity; analyses were not powered to detect statistically significant differences. Of 820 patients, 616 (75%) had unambiguous KRAS data; 316 (51%) had KRAS wild-type tumors and 300 (49%) had mutant KRAS tumors. The median progression-free survival (PFS) was 6.4 months for bevacizumab plus chemotherapy and 4.5 months for chemotherapy [P < 0.0001; HR = 0.61; 95% confidence interval (CI): 0.49–0.77] for wild-type KRAS and 5.5 and 4.1 months, respectively (P = 0.0027; HR = 0.70; 95% CI: 0.56–0.89) for mutant KRAS. The median overall survival (OS) was 15.4 and 11.1 months, respectively (P = 0.0052; HR = 0.69; 95% CI: 0.53–0.90) for wild-type KRAS and 10.4 versus 10.0 months, respectively (P = 0.4969; HR = 0.92; 95% CI: 0.71–1.18) for mutant KRAS. In both analyses, no treatment interaction by KRAS status was observed (PFS, P = 0.4436; OS, P = 0.1266). Bevacizumab beyond first progression represents an option for patients with mCRC treated with bevacizumab plus standard first-line chemotherapy, independent of KRAS status.